Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial.
Conclusions: The results did not raise any new safety concerns for ranibizumab. The findings allow conclusions to be drawn on how pharmacovigilance data can be collected even more effectively in real-world studies to facilitate discussion on benefit-risk ratio. PMID: 33083052 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - October 22, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Off-label use as a standard of care
In the October issue of the Journal, Brown et al report that three intravitreal VEGF-I ’s (vascular endothelial growth factor inhibitors), ranibizumab, aflibercept and bevacizumab, were cost-effective for the treatment of NVAMD (neovascular age-related macular degeneration). Further, they found that bevacizumab was several-fold more cost-effective than ranibizumab and aflibercept.1 While neither of us are pharmaco-epidemiologists, the methods used by this experienced group of researchers appear to be valid. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - October 14, 2020 Category: Opthalmology Authors: Gary D. Novack, Ala Moshiri Tags: Editorial Source Type: research

Ranibizumab for myopic choroidal neovascularization
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - October 13, 2020 Category: Drugs & Pharmacology Authors: Danny S. C. Ng Nicholas S. K. Fung Fanny L. T. Yip Timothy Y. Y. Lai Source Type: research

Vogt-Koyanagi-Harada: treatment of recurrence after administration of 3 intravenous bolus of 1g of corticosteroids and mycophenolate mofetil.
Authors: Aguilar-González M, Martínez-López-Corell P, Marín-Payá E, Díaz-Llopis M, Gallego-Pinazo R, Andreu-Fenoll M Abstract The case is presented on a young Honduran female with no medical history of note, who presented with multiple areas of exudative retinal detachment (RD), and a best-corrected visual acuity of 1.3logMAR in both eyes. She was diagnosed with incomplete Vogt-Koyanagi-Harada syndrome, and treated early with a combination of intravenous therapy with 1g of prednisolone per day for 3 days, as recommended by published evidence, as well as mycophenolate mofeti...
Source: Archivos de la Sociedad Espanola de Oftalmologia - October 11, 2020 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

Does Pharmaceutical Compounding of Vascular Endothelial Growth Factor Inhibitors for Intravitreal Use Alter the Risk of Post-injection Endophthalmitis?
CONCLUSION: Use of compounded anti-VEGF drugs in a large clinical setting was not associated with an altered risk of PIE. The finding adds to the evidence that splitting of vials into prefilled syringes for intravitreal injections is safe, provided that an appropriate pharmaceutical compounding procedure is strictly followed. PMID: 33026900 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - October 9, 2020 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration.
Authors: Wang Z, Li M, Yao Y, Hu J, Tang J, Tang R, Piao Z, Qu J Abstract Purpose: To study the short-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with conbercept and switched to ranibizumab or bevacizumab due to persistent activity. Methods: This retrospective single-arm study included nAMD patients who were followed up for at least three months after switching from at least 3 monthly intravitreal conbercept injections to bevacizumab or ranibizumab for persistent choroidal neovascularization (CNV) activity. The demograp...
Source: Journal of Ophthalmology - October 3, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Ten-year survival trends of neovascular age-related macular degeneration at first presentation.
CONCLUSIONS: The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes. PMID: 33011683 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - October 2, 2020 Category: Opthalmology Authors: Arpa C, Khalid H, Chandra S, Wagner S, Fasler K, Faes L, Pooprasert P, Chopra R, Moraes G, Balaskas K, Keane PA, Sivaprasad S, Fu DJ Tags: Br J Ophthalmol Source Type: research

Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome
Précis: Intravitreal anti-vascular endothelial growth factor therapy resulted in sustained elevation of intraocular pressure (IOP) in 18.6% of patients with coexisting age-related macular degeneration and pseudoexfoliation (PXF) syndrome. The development of sustained elevation of IOP after ~19 injections reflected the cumulative effect of anti-vascular endothelial growth factor injections on IOP. Purpose: The purpose of this study was to compare the long-term effect of intravitreal ranibizumab (IVR) and intravitreal bevacizumab (IVB) therapies on IOP in patients with and without PXF syndrome. Design: This wa...
Source: Journal of Glaucoma - October 1, 2020 Category: Opthalmology Tags: Original Studies Source Type: research

Progression of retinal ischemia in a case of macular telangiectasia type 1 after ranibizumab injection: optical coherence tomography angiography findings
Conclusion: Optical coherence tomography angiography may represent an indispensable diagnostic technique, complementary to traditional imaging, in the evaluation of the effects of anti–vascular endothelial growth factor therapy in patients with MacTel Type 1. (Source: Retinal Cases and Brief Reports)
Source: Retinal Cases and Brief Reports - September 22, 2020 Category: Opthalmology Tags: Case Report Source Type: research

Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients
The DRCR.net Protocol T clinical trial assessed the comparative efficacy and safety of anti-VEGF treatments including aflibercept, ranibizumab and bevacizumab in diabetic macular edema (DME). Post -hoc analyse... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - September 17, 2020 Category: Opthalmology Authors: J. M. Ruiz-Moreno, F. de Andr és-Nogales and I. Oyagüez Tags: Research article Source Type: research

Real-world outcomes after 36 months treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME)
Purpose: To assess the efficacy, safety and follow-up of 36 months treatment with ranibizumab in patients with diabetic macular edema (DME) in real life setting. Methods This is a prospective phase 4 observational study. Between December 2013 and April 2015, 84 ophthalmologists enrolled a total of 290 adult patients initiating ranibizumab for visual impairment due to diabetic macular edema (DME) and treated them according to their routine practice. The primary outcome (mean change in best-corrected visual acuity [BCVA] after 12 months) was previously reported. Here we present outcomes after 36 months of follow-up for BC...
Source: Ophthalmic Research - September 14, 2020 Category: Opthalmology Source Type: research

Late-phase hypercyanescence during indocyanine green angiography for assessment of myopic choroidal neovascularization.
CONCLUSIONS: Hypercyanescence on late-phase ICGA may assist in identifying more active mCNV requiring intensive treatment. PMID: 32900221 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - September 8, 2020 Category: Opthalmology Authors: Zhang T, Wang W, Li M, Huang Y Tags: Eur J Ophthalmol Source Type: research

Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab
This study searched for early predictive vascular biomarkers for visual outcomes in eyes with macular edema caused by branch retinal vein occlusion (BRVOME).MethodsTwenty-four eyes of 24 subjects with BRVOME were treated with the intravitreal injection of ranibizumab (IVR) for at least 6  months. We measured mean blur rate (MBR) in the optic nerve head (ONH) and vessel density (VD) in the macula with laser speckle flowgraphy and optical coherence tomography angiography, respectively.ResultsSix-month post-IVR best-corrected visual acuity (BCVA) was correlated positively with age, pre-IVR BCVA, 1-month post-IVR BCVA, 3-...
Source: International Ophthalmology - September 6, 2020 Category: Opthalmology Source Type: research

Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration.
Conclusion: This study demonstrates that most patients (74%) improve or maintain visual acuity long-term using a TAE model with a significant portion (45.1%) achieving 20/50 or better visual acuity with sustained treatment. PMID: 32864064 [PubMed] (Source: Journal of Ophthalmic and Vision Research)
Source: Journal of Ophthalmic and Vision Research - September 1, 2020 Category: Opthalmology Tags: J Ophthalmic Vis Res Source Type: research

Error in Text
In the Original Investigation titled “Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial,” published online July 30, 2020, an error appeared in the text. In the Methods section, the age of eligible participan ts should have been 50 years or older not 50 years or younger. The article has been corrected online. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - September 1, 2020 Category: Opthalmology Source Type: research

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in nAMD
This randomized clinical trial evaluates extended dosing with faricimab in patients with neovascular age-related macular degeneration (nAMD). (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - September 1, 2020 Category: Opthalmology Source Type: research

Safety and Efficacy of Faricimab vs Ranibizumab
This phase 2 randomized clinical trial assesses the efficacy and safety of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - September 1, 2020 Category: Opthalmology Source Type: research

Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
This randomized clinical trial (EVEREST II) compares intravitreal ranibizumab with or without verteporfin photodynamic therapy among Asian patients with polypoidal choroidal vasculopathy at 24 months. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - September 1, 2020 Category: Opthalmology Source Type: research

Creation of retinal vein occlusion model in cynomolgusmonkeys and determination of its pathological features.
CONCLUSION: We have created a non-human primate RVO model, which resembles the clinical RVO pathology. In this model, an injection of ranibizumab leads to a reduction in the vascular leakage and the retinal thickness and volume by blockingthe expression of VEGF. Our model might be useful for investigating the pathological mechanisms of RVOs and explore new therapeutic agents for RVO. PMID: 32867658 [PubMed - as supplied by publisher] (Source: Current Neurovascular Research)
Source: Current Neurovascular Research - August 30, 2020 Category: Neurology Authors: Inagaki S, Shimazawa M, Otsu W, Araki T, Numata Y, Nakamura S, Tsusaki H, Hara H Tags: Curr Neurovasc Res Source Type: research

The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.
Conclusions: This systematic review indicates that conbercept may achieve similar BCVA and CRT improvements as ranibizumab and aflibercept, with a superior rate of polyp regression at 12 months. PMID: 32855818 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - August 30, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema.
Conclusion: In DME patients, the CSCT decreases after 5 IVI of anti-VEGF, especially after aflibercept treatment. PMID: 32850142 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - August 29, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

One-year results of anti-vascular endothelial growth factor therapy combined with triamcinolone acetonide for macular edema associated with branch retinal vein occlusion
ConclusionThere were no clear differences between combination therapy of anti-VEGF with STTA and anti-VEGF monotherapy for the treatment of patients with ME associated with BRVO. The number of anti-VEGF injections in patients who received the combination therapy was not reduced as compared with the number of anti-VEGF injections in patients who received the monotherapy. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - August 27, 2020 Category: Opthalmology Source Type: research

Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis.
Authors: Gedar Totuk OM, Kanra AY, Bromand MN, Kilic Tezanlayan G, Ari Yaylalı S, Turkmen I, Ardagil Akcakaya A Abstract The aim of this study was to compare the effectiveness of intravitreal ranibizumab (IVR) injections for the treatment of diabetic macular edema (DME) in eyes with and without previous vitrectomy. The medical records of 28 eyes (11 vitrectomized and 17 nonvitrectomized) of 28 patients (mean age, 59.0 ± 9.6 years; male to female ratio 1 : 1) who were diagnosed with DME and had received IVR treatment were reviewed retrospectively. The indications of vitrectomy in ...
Source: Journal of Ophthalmology - August 26, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study
Purpose: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naive patients with neovascular age-related macular degeneration enrolled in LUMINOUS study. Methods: This 5-year, prospective, multicenter, observational study recruited 30,138 adult patients (treatment-naive or previously treated with ranibizumab or other ocular treatments) who were treated according to the local ranibizumab label. Results: Six thousand two hundred and forty-one treatment-naive neovascular age-related macular degeneration patients were recruited. Baseline (BL) demographics were, mean (SD) age...
Source: RETINA - August 26, 2020 Category: Opthalmology Tags: Original Study Source Type: research

Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti–vascular endothelial growth factor monotherapy
Conclusion: Laser, IVR, and IVB are effective for Type 1 ROP. Retinopathy of prematurity recurrence requiring re-treatment was encountered as late as 50 weeks of postmenstrual age after IVB or IVR but earlier after laser. Longer follow-up for infants treated with anti–vascular endothelial growth factor is needed, especially in patients with significant risk factors such as an early postmenstrual age at initial treatment, Zone I ROP, low Apgar score, and multiple births. (Source: RETINA)
Source: RETINA - August 26, 2020 Category: Opthalmology Tags: Original Study Source Type: research

A case of late-onset larynx angioedema after ranibizumab intravitreal injection: Ranibizumab-related angioedema.
This report suggests that, even in cases of intravitreal injection, patients with history of allergy, despite the anti-allergic treatment, should be hospitalized to detect late onset of such a life-threatening complication. PMID: 32820959 [PubMed - as supplied by publisher] (Source: International Journal of Immunopathology and Pharmacology)
Source: International Journal of Immunopathology and Pharmacology - August 23, 2020 Category: Allergy & Immunology Tags: Int J Immunopathol Pharmacol Source Type: research

Management of optic disc granuloma in a patient of miliary tuberculosis with intravitreal ranibizumab in addition to antitubercular therapy
Pooja Bansal, Ritesh NarulaIndian Journal of Ophthalmology 2020 68(9):1946-1947 (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - August 19, 2020 Category: Opthalmology Authors: Pooja Bansal Ritesh Narula Source Type: research

Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up.
Conclusions: This retrospective study of 180 nAMD patients treated with a TER of intravitreal anti-VEGF demonstrates an initial improvement of BCVA after loading phase, followed by long-term visual stabilization for at least six years. These results were obtained with a high number of injections, averaging close to six injections per year during long-term follow-up. In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used. PMID: 32802487 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - August 19, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Correlation of Response between Both Eyes to First and Second Line Anti-VEGF Therapy in Diabetic Macular Edema.
CONCLUSIONS: This study demonstrated a strong anatomical correlation responses between the eyes in patients with bilateral DME for both first-line bevacizumab therapy and second-line ranibizumab therapy. Response to second-line therapy was favorable and correlated among eyes regardless they were from the same or different individuals. PMID: 32804540 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - August 16, 2020 Category: Opthalmology Authors: Tiosano L, Ayalon A, Banin E, Averbukh E, Jaouni T, Chowers I Tags: Curr Eye Res Source Type: research

Yellow Subretinal Lesions following Initiation of Antituberculosis Therapy in A Tubercular Choroidal Granuloma: A Sign of Paradoxical Worsening?
CONCLUSION: Subretinal yellow-white lesions may develop as a paradoxical response to ATT. PMID: 32783681 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - August 14, 2020 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration : Long-term retinal changes under anti-vascular endothelial growth factor treatment.
CONCLUSION: Atrophic alterations of the retina and RPE are progressive and may partly be induced by anti-VEGF. Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients. PMID: 32761460 [PubMed - as supplied by publisher] (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - August 5, 2020 Category: General Medicine Authors: Ebner C, Wernigg C, Schütze C, Weingessel B, Vécsei-Marlovits PV Tags: Wien Klin Wochenschr Source Type: research

Intravitreal ranibizumab versus dexamethasone implant in macular edema due to branch retinal vein occlusion: Systematic review and meta-analysis.
CONCLUSION: Intravitreal RNB was more effective with less pronounced effect on IOP and cataract formation and/or progression compared to DII for patients with macular edema secondary to BRVO. PMID: 32757629 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - August 4, 2020 Category: Opthalmology Authors: Pranata R, Vania A, Vania R, Victor AA Tags: Eur J Ophthalmol Source Type: research

Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany.
Conclusion: Low number of visits as well as high number of treatment decisions without the use of OCT may contribute to undertreatment and poorer functional outcomes in patients undergoing ranibizumab treatment for nAMD in Germany. One potential reason for this could be that OCT was not covered by insurance for all patients during the study. PMID: 32724669 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - July 31, 2020 Category: Opthalmology Tags: J Ophthalmol Source Type: research

[The Microbiological Analysis of a Rhizobium radiobacter Outbreak After Intravitreal Injection].
This study is the first epidemic outbreak report of endophthalmitis caused by the same strain of R.radiobacter and the second article in which R.radiobacter was reported as the cause of endophthalmitis after intravitreal injection. PMID: 32723279 [PubMed - as supplied by publisher] (Source: Mikrobiyoloji Bulteni)
Source: Mikrobiyoloji Bulteni - July 30, 2020 Category: Microbiology Tags: Mikrobiyol Bul Source Type: research

Evaluation of surgical factors affecting vitreous hemorrhage following port delivery system with ranibizumab implant insertion in a minipig model
Conclusion: In this minipig surgical model of VH, scleral dissection followed by pars plana laser ablation before pars plana incision most effectively mitigated VH secondary to PDS implant insertion. (Source: RETINA)
Source: RETINA - July 30, 2020 Category: Opthalmology Tags: Original Study Source Type: research

REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study
Purpose: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). Methods: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. Results: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 1...
Source: RETINA - July 30, 2020 Category: Opthalmology Tags: Original Study Source Type: research

Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial
To evaluate if a combination therapy with micropulse diode laser (MPL) shows non-inferiority on visual acuity (BCVA) within 12  months in comparison to standard therapy, i.e. intravitreal injection of ranibizum... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - July 29, 2020 Category: Opthalmology Authors: Olga Furashova, Patrick Strassburger, Klio Ai Becker and Katrin Engelmann Tags: Research article Source Type: research

Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Conclusions: Ranibizumab and aflibercept presented similar anatomical and functional outcomes in 18-month follow-up in patients with DME. It is important to determine factors, affecting VA, so as to provide individualized treatment. PMID: 32722955 [PubMed - as supplied by publisher] (Source: Cutaneous and Ocular Toxicology)
Source: Cutaneous and Ocular Toxicology - July 28, 2020 Category: Toxicology Authors: Chatzirallis A, Theodossiadis P, Droutsas K, Koutsandrea C, Ladas I, Moschos MM Tags: Cutan Ocul Toxicol Source Type: research

Emerging drugs for the treatment of diabetic retinopathy.
Authors: Striglia E, Caccioppo A, Castellino N, Reibaldi M, Porta M Abstract INTRODUCTION: Diabetic retinopathy (DR) is one of the main pathological features of the diabetes mellitus spectrum. It is estimated that in 2020 about 4 million people worldwide suffered from blindness or visual impairment caused by DR. Many patients cannot access treatment, mostly because of high costs, while others discontinue it prematurely due to the high number of intravitreal administrations required, or the occurrence of ocular complications, or discomfort in quality of life. AREAS COVERED: The aims of this paper are to summariz...
Source: Expert Opinion on Emerging Drugs - July 28, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect.
CONCLUSION: IVR conforms to the previously described regression patterns following intravitreal bevacizumab for ROP indicative of a class effect. Follow-up using FA might help to optimize the management of these infants after injection of the drug. PMID: 32722932 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 27, 2020 Category: Opthalmology Authors: Ji MH, Moshfeghi DM, Shields RA, Bodnar Z, Ludwig CA, Callaway NF, Orazi L, Amorelli GM, Lepore D Tags: Eur J Ophthalmol Source Type: research

Cost-minimization Analysis of Ranibizumab versus Aflibercept in the Treatment of Neovascular Age-related Macular Degeneration in Colombia
. (Source: Ophthalmic Epidemiology)
Source: Ophthalmic Epidemiology - July 26, 2020 Category: Opthalmology Authors: Juan Camilo S ánchez-Thorin Source Type: research

Optical coherence tomography angiography in Tuberous sclerosis complicated with macular choroidal neovascularization.
This study describe the optical coherence tomography angiography (OCTA) features of a young patient with Tuberous sclerosis complicated with CNV unilateral macular choroidal neovascularization during the ranibizumab therapy. OCTA scans of macular region of right eye, revealed a dense microvascular network confirming the diagnosis of CNV. After four monthly intravitreal injections, OCTA revealed a decrease of size and activity of CNV. OCTA is a valid, non-invasive, dyeless, and reliable method that could improve the diagnosis and management of CNV in child with Tuberous sclerosis. PMID: 32715772 [PubMed - as supplied b...
Source: European Journal of Ophthalmology - July 26, 2020 Category: Opthalmology Authors: Fortunato M, Turtoro A, Cennamo G, Nardella C Tags: Eur J Ophthalmol Source Type: research

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment na ïve and refractory macular oedema in branch retinal vein occlusion.
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion. Eur J Ophthalmol. 2020 Jul 24;:1120672120945103 Authors: Elkazza SA, Hogg HJ, Di Simplicio S, Dlay SS PMID: 32703021 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - July 23, 2020 Category: Opthalmology Authors: Elkazza SA, Hogg HJ, Di Simplicio S, Dlay SS Tags: Eur J Ophthalmol Source Type: research

Corrigendum to "Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy".
Corrigendum to "Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy". Biomed Res Int. 2020;2020:6219089 Authors: Toto L, Evangelista F, Viggiano P, Erroi E, D'Onofrio G, Libertini D, Porreca A, D'Aloisio R, Parravano M, Di Antonio L, Di Nicola M, Mastropasqua R Abstract [This corrects the article DOI: 10.1155/2020/9496242.]. PMID: 32695816 [PubMed - in process] (Source: Biomed Res)
Source: Biomed Res - July 23, 2020 Category: Research Authors: Toto L, Evangelista F, Viggiano P, Erroi E, D'Onofrio G, Libertini D, Porreca A, D'Aloisio R, Parravano M, Di Antonio L, Di Nicola M, Mastropasqua R Tags: Biomed Res Int Source Type: research

Time course of changes in contrast sensitivity following intravitreal ranibizumab injection for branch retinal vein occlusion
AbstractPurposeTo evaluate contrast sensitivity (CS) in patients with branch retinal vein occlusion (BRVO) following intravitreal ranibizumab injection (IVR), and to investigate the relationship between CS and retinal microstructure.DesignA retrospective, observational case series.MethodsWe included 23 eyes with treatment na ïve BRVO followed up for 6 months after treatment. Best-corrected visual acuity (BCVA), letter contrast sensitivity (LC), and 10% low contrast visual acuity (LCVA) were measured. All tests were performed before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on optical coherence t...
Source: Japanese Journal of Ophthalmology - July 20, 2020 Category: Opthalmology Source Type: research

Lung cancer and intraocular metastasis in gestation: Clinical experiences of a rare case
We here report an extremely rare case of a 31 ‐year‐old non‐smoking pregnant female who was diagnosed as lung adenocarcinoma with multiple metastasis including choroid metastasis. Whole exon sequencing was performed but no appropriate therapeutic target has been identified. Lung cancer in pregnancy combined with intraocular metastasis rarely occurs and has a poor prognosis. Here, we report an extremely rare case of a 31 ‐year‐old non‐smoking pregnant female who was diagnosed with lung adenocarcinoma with multiple metastasis including choroidal metastasis. Whole exon sequencing was performed but no appropriate t...
Source: Thoracic Cancer - July 20, 2020 Category: Cancer & Oncology Authors: Lin Lin, Jing Sun, Jie Wang Tags: CASE REPORT Source Type: research

The Role of Optical Coherence Tomography Angiography in Ranibizumab-Treated Choroidal Neovascularization in Choroidal Osteoma
In this study, we report the initial evaluation of choroidal neovascularization (CNV) secondary to choroidal osteoma and subsequent response to anti-vascular endothelial growth factor (anti-VEGF) treatment monitored with optical coherence tomography angiography (OCT-A). A 38-year-old female presented with an initial visual acuity of 20/150 in the left eye. Clinical examination revealed a choroidal osteoma. OCT demonstrated both subretinal and intraretinal fluid. OCT-A was performed and showed CNV. A course of ten treatments with ranibizumab showed an improvement of visual acuity to 20/30 –3, improvement of subretinal...
Source: Case Reports in Ophthalmology - July 17, 2020 Category: Opthalmology Source Type: research

Herpetic Keratouveitis following Intravitreal Ranibizumab Injection in a Case with Diabetic Macular Edema.
CONCLUSION: Herpetic keratouveitis can be seen as a rare complication of intravitreal ranibizumab injection. To our best knowledge, this is the first case with herpes keratouveitis developed following intravitreal ranibizumab injection. PMID: 32657646 [PubMed - as supplied by publisher] (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - July 15, 2020 Category: Allergy & Immunology Tags: Ocul Immunol Inflamm Source Type: research

A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States
To perform a societal cost-benefit analysis comparing intravitreal bevacizumab (Avastin ®), ranibizumab (Lucentis®) and aflibercept (Eylea®) monotherapies for treating neovascular age-related macular degeneration (NVAMD). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - July 14, 2020 Category: Opthalmology Authors: Gary C. Brown, Melissa M. Brown, Sara B. Rapuano, David Boyer Tags: Original Articles Source Type: research

Beyond antibodies: ankyrins and DARPins. From basic research to drug approval.
Abstract This Pharmacological Perspective describes the pathway that, starting from the deep understanding of ankyrins - a family of proteins with high variability-binding and high specificity-binding characteristics - led to the development of a new class of recombinant-binding proteins, the DARPins (designed ankyrin repeat proteins). These are envisaged as alternatives to mAbs and related biologics, with the potential to overcome certain shortcomings of mAbs. DARPins have relatively low molecular weights (14-21kDas) and more favorable PK profiles than mAbs, are stable proteins that can be easily produced in Esch...
Source: Current Opinion in Pharmacology - July 12, 2020 Category: Drugs & Pharmacology Authors: Caputi AP, Navarra P Tags: Curr Opin Pharmacol Source Type: research